GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Net Margin %

Myovant Sciences (Myovant Sciences) Net Margin % : -57.50% (As of Dec. 2022)


View and export this data going back to 2016. Start your Free Trial

What is Myovant Sciences Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Myovant Sciences's Net Income for the three months ended in Dec. 2022 was $-57.6 Mil. Myovant Sciences's Revenue for the three months ended in Dec. 2022 was $100.2 Mil. Therefore, Myovant Sciences's net margin for the quarter that ended in Dec. 2022 was -57.50%.

The historical rank and industry rank for Myovant Sciences's Net Margin % or its related term are showing as below:

MYOV' s Net Margin % Range Over the Past 10 Years
Min: -430.12   Med: -259.65   Max: -48.47
Current: -48.47


MYOV's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -162.58 vs MYOV: -48.47

Myovant Sciences Net Margin % Historical Data

The historical data trend for Myovant Sciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Net Margin % Chart

Myovant Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Net Margin %
Get a 7-Day Free Trial - - - -430.12 -89.18

Myovant Sciences Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -116.54 -102.98 -18.23 -43.52 -57.50

Competitive Comparison of Myovant Sciences's Net Margin %

For the Biotechnology subindustry, Myovant Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myovant Sciences's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Net Margin % falls into.



Myovant Sciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Myovant Sciences's Net Margin for the fiscal year that ended in Mar. 2022 is calculated as

Net Margin=Net Income (A: Mar. 2022 )/Revenue (A: Mar. 2022 )
=-205.981/230.972
=-89.18 %

Myovant Sciences's Net Margin for the quarter that ended in Dec. 2022 is calculated as

Net Margin=Net Income (Q: Dec. 2022 )/Revenue (Q: Dec. 2022 )
=-57.627/100.229
=-57.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myovant Sciences  (NYSE:MYOV) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Myovant Sciences Net Margin % Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Myovant Sciences (Myovant Sciences) Business Description

Traded in Other Exchanges
N/A
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Lauren Merendino officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David C Marek director, officer: Principal Executive Officer C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Matthew Lang officer: General Counsel & Corp. Secy. C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Ferreira Juan Camilo Arjona officer: Chief Medical Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Uneek Mehra officer: Principal Financial Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Shigeyuki Nishinaka director 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Nancy Valente director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Terrie Curran director C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe officer: Principal Fin'l & Accounting C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Kim Sablich officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Hiroshi Nomura director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Adele M. Gulfo director ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957